These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24722365)

  • 21. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
    Wang C; Valera L; Jia L; Kirk MJ; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):611-3. PubMed ID: 23089758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
    Fridell RA; Qiu D; Valera L; Wang C; Rose RE; Gao M
    J Virol; 2011 Jul; 85(14):7312-20. PubMed ID: 21593143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between NS5A dimerization and hepatitis C virus replication.
    Lim PJ; Chatterji U; Cordek D; Sharma SD; Garcia-Rivera JA; Cameron CE; Lin K; Targett-Adams P; Gallay PA
    J Biol Chem; 2012 Aug; 287(36):30861-73. PubMed ID: 22801423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV NS5A inhibitors in development.
    Suk-Fong Lok A
    Clin Liver Dis; 2013 Feb; 17(1):111-21. PubMed ID: 23177287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
    PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.
    Barakat KH; Anwar-Mohamed A; Tuszynski JA; Robins MJ; Tyrrell DL; Houghton M
    J Chem Inf Model; 2015 Feb; 55(2):362-73. PubMed ID: 24730573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus.
    Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH
    J Chin Med Assoc; 2019 May; 82(5):368-374. PubMed ID: 30920421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
    Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Peng X; Wang C; Ying L; Cao H; Lawitz E; Poordad F; Rondon J; Box TD; Zeuzem S; Buggisch P; Lin K; Qiu YL; Jiang L; Colvin R; Or YS
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6207-15. PubMed ID: 27503640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
    Herbst DA; Reddy KR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visualisation and analysis of hepatitis C virus non-structural proteins using super-resolution microscopy.
    Bartlett C; Curd A; Peckham M; Harris M
    Sci Rep; 2018 Sep; 8(1):13604. PubMed ID: 30206266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
    McPhee F; Hernandez D; Zhou N
    Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
    Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
    J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.
    Nettles JH; Stanton RA; Broyde J; Amblard F; Zhang H; Zhou L; Shi J; McBrayer TR; Whitaker T; Coats SJ; Kohler JJ; Schinazi RF
    J Med Chem; 2014 Dec; 57(23):10031-43. PubMed ID: 25365735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.